美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

F/m Emerald Life Sciences Innovation ETF

45.14

-0.9465-2.05%

盤後：45.350.2115+0.47%19:30 EDT

成交量：985

成交額：4.48萬

市值：1.24億

市盈率：- -

高：45.44

開：45.44

低：45.14

收：46.09

52周最高：48.78

52周最低：29.13

股本：275.70萬

流通股本：275.70萬

量比：0.41

換手率：0.04%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

重發-第4次更新-美國衞生部長小肯尼迪向關鍵衞生委員會增補了八名新成員

Cogent Biosciences宣佈FDA受理Bezuclastinib治療晚期系統性肥大細胞增多症的新藥申請

Guardant Health與Evernorth旗下Evicore達成協議，Shield血液檢測自2027年1月1日起納入結直腸癌篩查覆蓋範圍

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率

Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷

Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例

Cogent Biosciences協議生效：為期五年，自動續約兩年——SEC文件披露

美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極

藥聞 | 英硅智能上市後首份半年報扭虧創新藥研發加速擁抱AI

聯環藥業上半年扭虧為盈集採續採與創新藥研發協同推進

博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑

BUZZ——美國股市動態-Semtech、唐納森、Meta

Spyre股價下跌，因關節炎藥物未達研發目標

Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻

Spyre Therapeutics公司——療效幅度未達公司預設目標，類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整

Spyre Therapeutics公司：Spy072聯合Il17-a/F治療化膿性汗腺炎（HS）預計於2027年末或2028年初啓動

Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢

Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果

美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/LFSC/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.1385,"timestamp":1789761600000,"preClose":46.085,"halted":0,"volume":985,"hourTrading":{"tag":"盘后","latestPrice":45.35,"preClose":45.1385,"latestTime":"19:30 EDT","volume":9,"amount":406.2465,"timestamp":1789774205193,"change":0.2115,"changeRate":0.004686,"amplitude":0},"delay":0,"changeRate":-0.02053813605294565,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"休市中","change":-0.9465,"latestTime":"09-18 16:00:00 EDT","open":45.44,"high":45.44,"low":45.1385,"amount":44760.44289,"amplitude":0.006542,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":46.085,"sharesOutstanding":2657035,"nav":46.11,"aum":127587983.85,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.35,"preClose":45.1385,"latestTime":"19:30 EDT","volume":9,"amount":406.2465,"timestamp":1789774205193,"change":0.2115,"changeRate":0.004686,"amplitude":0},"volumeRatio":0.4080702474412452},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4080702474412452,"shares":2757035,"dividePrice":0,"high":45.44,"amplitude":0.006542,"preClose":46.085,"low":45.1385,"week52Low":29.13,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.1385,"eps":0,"divideRate":0,"volume":985,"delay":0,"ttmEps":0,"open":45.44,"prevYearClose":36.6147,"prevWeekClose":45.3275,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":45.3275,"twentyDayClose":47.4404,"sixtyDayClose":43.2903},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668942109","title":"重發-第4次更新-美國衞生部長小肯尼迪向關鍵衞生委員會增補了八名新成員","url":"https://stock-news.laohu8.com/highlight/detail?id=2668942109","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668942109?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 03:56","pubTimestamp":1789674961,"startTime":"0","endTime":"0","summary":"小肯尼迪已对多个联邦卫生咨询机构进行了重组，包括疾病控制与预防中心的疫苗咨询委员会——他在去年解散整个委员会后，重新任命了其成员。美国最高法院去年6月作出的一项裁决 ，确认了小肯尼迪对预防保健委员会的管辖权。该裁决后的11月会议因2025年政府停摆而未能举行。今年5月，小肯尼迪解除了该有影响力的工作组主席和副主席的职务。路透联系美国卫生与公众服务部时，该部拒绝就专家小组下次会议的日期置评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4S4591O0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4535","GNMX","LU0109394709.USD","FFOX","LU0320765992.SGD","BK4588","PTH","HELX","BK4585","GDOC","GNOM","LFSC","EKG","GH","LU0889565916.HKD","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168602224","title":"Cogent Biosciences宣佈FDA受理Bezuclastinib治療晚期系統性肥大細胞增多症的新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1168602224","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168602224?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 20:01","pubTimestamp":1789473701,"startTime":"0","endTime":"0","summary":"Cogent Biosciences今日宣布，美国食品药品监督管理局已正式受理其针对Bezuclastinib的新药申请，该药物拟用于治疗晚期系统性肥大细胞增多症患者。因此，Cogent Biosciences此番取得的阶段性成果，无疑受到了医学界和投资圈的广泛关注。Bezuclastinib作为一种高选择性KIT D816V突变抑制剂，其设计初衷正是为了精准靶向驱动AdvSM等疾病的核心致病机制。随着NDA获得受理，后续的审评沟通及潜在的获批上市进程也将逐步展开，业界正持续跟踪该药物的监管动态与临床数据表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","LFSC","BK4139","BK4505","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103100254","title":"Guardant Health與Evernorth旗下Evicore達成協議，Shield血液檢測自2027年1月1日起納入結直腸癌篩查覆蓋範圍","url":"https://stock-news.laohu8.com/highlight/detail?id=1103100254","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103100254?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:08","pubTimestamp":1789416490,"startTime":"0","endTime":"0","summary":"Guardant Health公司宣布，Evernorth旗下的Evicore已决定将其Shield血液检测纳入结直肠癌（CRC）筛查的承保范围。这项覆盖计划将于2027年1月1日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","GNMX","BK4588","LU0320765992.SGD","GH","LU0109394709.USD","HELX","GNOM","PTH","LU0889565916.HKD","BK4585","FFOX","LFSC","BK4551","GDOC","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SBIO","FBT","BIB","AZNH","GNOM","WDNA","BK4588","IBB","RSPH","BK4585","PSCH","HELX","IBRN","BBP","MRNY","PBE","FTXH","IYH","IDNA","BIOY","LU1992135472.HKD","LU2272731865.HKD","PJP","MRNX","LU2272731600.USD","IEIH","LU2322448791.USD","LU2322448957.HKD","XPH","LU2272731782.SGD","XBIX","IE00B5TLWC47.USD","BBH","CANC","SYNB","LU1992135399.USD","TMED","BME","IEHS","LFSC","PBPH","PPH","RXL","LU2473716301.USD","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121233294?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116354483","title":"Guardant Health重磅里程碑：Guardant360® Cdx獲FDA批准，成為阿斯利康Ectamah™（Camizestrant）晚期乳腺癌伴隨診斷","url":"https://stock-news.laohu8.com/highlight/detail?id=1116354483","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116354483?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 06:11","pubTimestamp":1788559873,"startTime":"0","endTime":"0","summary":"Guardant Health今日宣布，其Guardant360 Cdx液体活检产品已获得美国食品药品监督管理局的里程碑式批准，正式成为阿斯利康新型内分泌疗法Ectamah在晚期乳腺癌治疗中的伴随诊断工具。Guardant Health管理层在声明中表示，这一里程碑不仅是对公司技术实力的权威认可，更是对癌症患者个体化治疗承诺的有力践行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","EKG","GDOC","PTH","BK4588","GNMX","LU0889565916.HKD","BK4585","FFOX","LFSC","LU0320765992.SGD","GNOM","BK4551","HELX","LU0109394709.USD","BK4196","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107575074","title":"Cogent Biosciences將向Hovione採購Bezuclastinib產品最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1107575074","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107575074?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 04:14","pubTimestamp":1788380059,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 已通过SEC文件披露，计划向Hovione采购Bezuclastinib产品的指定最低比例份额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","COGT","CANC","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126702774","title":"Cogent Biosciences協議生效：為期五年，自動續約兩年——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1126702774","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126702774?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 04:13","pubTimestamp":1788379990,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. 的某项协议已正式生效，其初始期限设定为五年。根据美国证券交易委员会（SEC）的备案文件，该协议条款中包含自动续约机制——每当五年期限届满，协议将自动延长两年。这一续约安排，为合作双方的长期关系提供了延续性预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COGT","LFSC","BK4505","BK4139","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股異動丨諾華製藥升逾7%，多發性硬化症口服藥後期臨床試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664521258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PSCH","PBE","IE0009355771.USD","PPH","HELX","LFSC","RXL","SYNB","BK4007","LU0211331839.USD","BBP","IEIH","MRNX","AZNH","FTXH","LU2473716301.USD","FBT","MEDX","TMED","BME","BIOY","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","PBPH","LU2272731600.USD","BK4585","IYH","SBIO","BIB","XPH","BK4588","IE0002141913.USD","LU2322448957.HKD","MEDI","RSPH","XBIX","MRNY","GNOM","IEHS","IDNA","IBB","IE00BFTCPJ56.SGD","PJP","WDNA","NVS","IE00B4R5TH58.HKD","CANC","IBRN","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"藥聞 | 英硅智能上市後首份半年報扭虧 創新藥研發加速擁抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHAT","XLVI","GDOC","QTOC","VTHR","IPOS","WRND","BK4585","AIPO","APXH","PBE","SBIO","GSKH","AGIX","BIOY","BK4588","ARTY","BBP","LFSC","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"聯環藥業上半年扭虧為盈 集採續採與創新藥研發協同推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_tw&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","BK4588","PBE","BIOY","BK0239","600513","BBP","IBB","SBIO","XLVI","GDOC","LFSC","WRND","BK4585","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博濟醫藥2026年半年報：創新藥研發需求復甦，在手訂單充足，經營現金流明顯下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LFSC","WRND","BK4588","XLVI","SPHQ","APXH","BIOY","GDOC","IBB","GSKH","BBP","BK0216","SBIO","159399","300404","PBE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662571159","title":"BUZZ——美國股市動態-Semtech、唐納森、Meta","url":"https://stock-news.laohu8.com/highlight/detail?id=2662571159","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662571159?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 20:32","pubTimestamp":1787747524,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Semtech、唐纳森、Meta工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透8月26日-周三，美国股指期货基本持平，因投资者在人工智能龙头企业Nvidia(辉达/英伟达)公布财报以及可能影响利率预期的备受关注的通胀报告发布前保","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4S44N0Y5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","VOX","LU1935043023.USD","LU1400636491.USD","LU1861215975.USD","BK4581","LU0823414478.USD","LU2265009873.SGD","3NVD.UK","BK4538","IE00BJLML261.HKD","FBX","LU1074936037.SGD","TRUP","LU1116320901.HKD","LU1043141396.HKD","LU2361044949.HKD","LU1934455277.USD","SG9999001176.SGD","LU2236285917.USD","LU2394011477.USD","LU0433182093.SGD","IE00BHPRN162.USD","LU0053666078.USD","IE00BD6J9T35.USD","LU0949170772.SGD","METV","AIFD","LU0823416689.USD","LU0323591593.USD","LU1267930573.SGD","BK4505","LU1923623000.USD","LU0395794307.EUR","GB00B4QBRK32.GBP","LU0690374615.EUR","IE00B775SV38.USD","LU1435385759.SGD","LU1697837992.HKD","LU2028103732.USD","PLTY","ABFL","LU1732799900.SGD","LU0980610538.SGD","LU2756315318.SGD","HK0000304805.HKD","LU3102509885.SGD","BK4579","LU0823417737.USD","LU1645745479.HKD","LU2471134796.USD","LU2999663052.SGD","07788","LU2168564065.EUR","LU2552382132.HKD","NVDB","LU0477156797.USD","ILDR","LU2168564149.EUR","LU1202635105.USD","LU2458330243.SGD","LU2095319765.USD","SG9999018857.SGD","ESLG","LU0494093205.USD","BK4543","SG9999014567.USD","IE000KEQY171.SGD","SG9999004303.SGD","BK4567","LU0784383803.USD","LU2264538146.SGD","LU1670710588.SGD","CMAG","LU2237443978.SGD","LU0354030511.USD","LU0096362180.USD","LU0130103400.USD","LU0823414551.USD","LU1236620834.HKD","SG9999015978.USD","BK4585","TTXU","NULC","IE000F7OJYX1.SGD","LU0054578231.USD","LTL","LU2750360997.AUD","LU1061106388.HKD","GAMR","TEK","LU2290526834.HKD","LU0820561909.HKD","IE0000B7K699.USD","NVDW","LU2168564222.USD","IE00BQXX3F31.USD","LU2403377893.USD","LU0708994859.HKD","LU1699723380.USD","LU2491050071.SGD","PLT","IE000SO60NU8.SGD","CLOD","BK4551","CRMG","CHAT","LU1571399168.USD","NVC","LU1951198990.SGD","IE00B19Z9505.USD","BK4161","GUNZ","LU0640476718.USD","LU2462157665.USD","SG9999001176.USD","LU1923622291.USD","LU1244550221.USD","NVDS","LU0553294199.USD","WISE","LU0133085943.USD","LU0130518102.USD","IETC","CRM","LU2065170008.USD","LFGY","SNPE","LU1400636574.HKD","LU2413666426.HKD","NVDQ","SOXX","LU0070302665.USD","LU2023250843.SGD","LU1868837136.USD","IE00BK4W5M84.HKD","LU1400636657.SGD","LU2087625088.SGD","SMHX","LU1232071149.USD","BK4554","LU0820562030.AUD","LU1670756490.USD","SMTG","LU1988902786.USD","IE00B7KXQ091.USD","LU0742534661.SGD","SGXZ81514606.USD","SGXZ31699556.SGD","ZM","BK4534","LU1059921491.USD","LU0348723411.USD","XLK","BK4549","IE00BFTCPJ56.SGD","LU0345774391.USD","LU0823421416.USD","2NVD.UK","LU0726765562.USD","LU0072462426.USD","IE00B19Z3B42.SGD","SG9999015986.USD","CNEQ","LU0158827781.USD","LU0823434740.USD","LU0072461881.USD","IE000BZT7R73.USD","LU2362541273.HKD","LU0205194284.USD","LU1633808545.USD","LU2322448791.USD","IE000W1ABFV2.USD","LU2360107168.USD","LU2087621335.USD","LU0267386448.USD","LU0724617625.USD","LU1861559042.SGD","SGXZ23171101.USD","LU0011850046.USD","LU0080751232.USD","LU2191332357.HKD","LU2272731600.USD","IE0005OL40V9.USD","LU2125154778.USD","LU0251132253.USD","LU1670711040.USD","USD","PLTG","LU0426412945.USD","BK4162","LU0061474705.USD","LU1093756168.USD","LU0205193047.USD","HK0000532082.HKD","LU1941712264.USD","IE00BN29S564.USD","LU2505996681.GBP","NOWL","LU0198837287.USD","BK4592","LU0154236417.USD","LU1037948897.HKD","METQ","LU1323610961.USD","IE00B894F039.SGD","LU0276348264.USD","HK0000320264.USD","LU1564329628.SGD","LU2756315664.SGD","LU1429558221.USD","LU0957791311.USD","LU0234572021.USD","IE00B1XK9C88.USD","LU0444971666.USD","IE0001KFT4U8.USD","BK4598","LU0477156953.USD","LU2954938101.SGD","LU0472753341.HKD","LU0106261372.USD","USXF","THMR","BK4605","SG9999000418.SGD","NOW","LU1934455194.USD","IE0009356076.USD","LU0158827948.USD","IE00BMPRXR70.SGD","IE000MB6IJN5.SGD","LU2213496289.HKD","LU1803068979.SGD","LU2506952097.USD","LU1670628061.USD","SG9999001077.SGD","LU2106854487.HKD","IE00B4YYXB79.USD","LU0057025933.USD","LU2023250504.SGD","BK4139","SG9999002224.SGD","IE00BYXW3230.USD","LU2133065610.SGD","LU2360106780.USD","BK4533","SYRE","LU0965509010.AUD","LU2347655073.USD","FBL","LU2362540622.SGD","LU1267930490.SGD","LU0950375773.USD","LU2463028550.USD","LU0882574055.USD","LU1868837300.USD","LU0107464264.USD","SG9999014559.SGD","IE00BKVL7J92.USD","LU0143551892.USD","LU0077335932.USD","LU1242518931.SGD","LU1623119135.USD","LU1642822529.SGD","LU2097829019.USD","SG9999014906.USD","SG9999014914.USD","LU2506952170.USD","SMH","LU0170899867.USD","LU1718418525.SGD","DIPS","IE00BJJMRX11.SGD","LU0738911758.USD","LU1267930730.SGD","LU1720051108.HKD","LU2237957811.SGD","DCI","LU2047632596.USD","LU2456880835.USD","LU2125909916.SGD","LU2089283258.USD","LU2210149790.SGD","LU0787776722.HKD","EFIV","LU1366192091.USD","LU2404859667.USD","LU2326559502.SGD","LU2750360641.GBP","LU0056508442.USD","IE00B5TLWC47.USD","LU2065171402.SGD","ROM","NVDO","IE0003U64NQ7.SGD","SGXZ51526630.SGD","LU2279689827.SGD","LU2210150020.SGD","LU1023059063.AUD","METG","SMTC","LU1934455863.HKD","ARTY","LU0557290698.USD","RSPC","IE000Q6AESB8.SGD","LU1868836757.USD","LU2237957902.USD","BK4612","LU0162691827.USD","FAI","IE00BFSS7M15.SGD","LU1548497426.USD","NVD","LU2430703251.USD","LU2420271590.USD","LU2637965513.SGD","SG9999014880.SGD","NVIW.SI","LU1992135399.USD","XDAT","LU0661504455.SGD","LU1923622614.USD","LU1144417596.USD","IE000ITXATA3.USD","LU2089284900.SGD","LU1280957306.USD","PLTR","FTEC","SPLTRmain","LU0868494617.USD","LU0889566641.SGD","LU1914381329.SGD","LU2111349929.HKD","LU2430703095.HKD","LU0354030438.USD","LU0265550359.USD","IE000YTNTUN2.SGD","HK0000306701.USD","LU0957808578.USD","LU1551013342.USD","LU1861220033.SGD","IE0009G5SDU7.USD","LU0786609619.USD","LU2249611893.SGD","LFSC","LU0256863811.USD","LU1868836914.USD","SNVD.UK","LU2552382058.USD","LU1983299246.USD","LU2065171311.SGD","IE0004091025.USD","NVDA","LU1721428933.USD","LU0965508806.USD","LU1066053197.SGD","LU0203202063.USD","LU1201861165.SGD","LU0345768153.USD","LU1496350171.SGD","LU1043141123.HKD","LU1880398554.USD","LU0289739343.SGD","IE00BJJMRZ35.SGD","IGV","SHLD","BK4528","METU","LU0390134368.USD","LU2452424414.USD","IE00BKDWB100.SGD","LU1989764664.SGD","LU1732800096.USD","IE00BDRTCR15.USD","LU2237443895.HKD","BK4097","LU2360032135.SGD","PLTI","LU0097036916.USD","PTIR","IE00B19Z8X17.USD","LU2361045086.USD","LU1880398471.USD","LU1145028129.USD","IE0004445015.USD","LU0096364046.USD","LU1236620750.USD","LU2324357040.USD","LU0006306889.USD","TRUC","IE00BJTD4V19.USD","LU2491049909.HKD","SOXQ","LU2746668461.USD","LU2054465674.USD","LU2505996509.AUD","LU2237438978.USD","SG9999018865.SGD","GXPC","BK4023","LU1989772923.USD","LU0289961442.SGD","LU0210533765.USD","LU0048584097.USD","LU0251142724.SGD","LU0528227936.USD","LU0861579265.USD","LU0128525929.USD","LU1629891620.HKD","LU1116320737.USD","IE00B3SWFQ91.USD","BK4141","LU2063271972.USD","LU0795875169.SGD","LU2487616109.SGD","HK0000320223.HKD","IE00BKPKM429.USD","LU1815333072.USD","LU0545039389.USD","METD","LU1201861249.SGD","LU2361044865.SGD","HK0000914686.HKD","LU1153585028.USD","BK4532","LU0417517546.SGD","ESUM","LU2272731782.SGD","IE00BFXG0V08.USD","ADBG","LU2461242641.AUD","LU1989772840.SGD","LU2083900584.USD","NVDL","SG9999002232.USD","LU2602419157.SGD","PLTD","LU2286300806.USD","PLTA","LU1496350502.SGD","SHOC","IE00BQXX3D17.EUR","SOCL","LU1003077747.HKD","LU0109391861.USD","LU0308772762.SGD","LU2250418816.HKD","SG9999017495.SGD","NVD2.UK","NVDG","VGT","IE00BZ9MQY76.HKD","LU1084165304.USD","IE0004086264.USD","CLSE","LU0432979614.USD","LU0784385170.HKD","LU1235294995.USD","LU1366333091.USD","LU2023251221.USD","HK0000304797.USD","IE000WAW04H5.SGD","LU0234570918.USD","LU1242518857.USD","LU0965509283.SGD","BK4548","LU1791710400.SGD","LU0320765059.SGD","LU2065169927.USD","SG9999013999.USD","LU0795875086.SGD","IE00BJT1NW94.SGD","IE00BZ199S13.USD","LU0985320562.USD","LU2413666699.HKD","LU2362541513.USD","LU0345769631.USD","LU2381873111.SGD","LU0310799852.SGD","LU0174119429.USD","LU0128525689.USD","LU1821325948.USD","LU0211327993.USD","LU0889565833.HKD","LU1823568750.SGD","LU2322448957.HKD","LU2247934214.USD","LU2592432038.USD","BK4566","LU2097344431.USD","LU0426417589.USD","LU2543165471.USD","BSX","CHPX","IE0034235188.USD","LU2506951875.HKD","LU2092627202.USD","INTU","LU1778281490.HKD","HK0000306685.HKD","BBWI","LU1057294990.SGD","LU0289960550.SGD","NVD3.UK","LU2112291526.USD","BK4547","TRFK","LU0476273544.USD","IE00BYQQ9H92.USD","BK4200","LU0784385840.USD","BK4527","LU2317271919.USD","LU0345768740.USD","LU0784384876.USD","BK4550","PLTZ","LU1489326972.SGD","LU2491050154.USD","LU1720051017.SGD","LU0211331839.USD","LU0149725797.USD","LU2125909759.SGD","TYLG","LU0964807845.USD","LU0157215616.USD","LU0965509101.SGD","NVII","SGXZ80539844.SGD","LU0274383776.USD","LU2433249047.HKD","LU2237443382.USD","LU0106261612.USD","LU2100268510.USD","FBYY","LU0642271901.SGD","LU0061474960.USD","LU1670627923.USD","LU2097344357.USD","LU2089985449.USD","LU0823417653.USD","LU1861558580.USD","BK4608","LU0215105999.USD","LU2347655156.SGD","LU1951200564.SGD","NOWX","LU0130102774.USD","07388","LU0444973449.USD","LU0942090050.USD","LU1316542783.SGD","SG9999015341.SGD","LU0511384066.AUD","NVDY","VT","IE00BMPRXQ63.HKD","IE0034235295.USD","LU1935043536.SGD","BK4077","BK4587","GB00BDT5M118.USD","SG9999015952.SGD","LU0079474960.USD","LU0122379950.USD","LU0345769128.USD","LU0048573561.USD","SGXZ99366536.SGD","IE00BFSS8Q28.SGD","PLTW","GB00B4LPDJ14.GBP","BK4607","LU1066051498.USD","LU0070217475.USD","LU1917777945.USD","LU2764263203.CNY","LU1935042488.USD","LU0320765489.SGD","LU0203345920.USD","LU2462591350.SGD","BK4561","LU0211328371.USD","IE00B3S45H60.SGD","LU0081259029.USD","LU2242649171.HKD","LU1852331112.SGD","SG9999015358.SGD","LU1037948541.HKD","LU2092937148.SGD","LU0792757196.USD","LU0466842654.USD","LU0052756011.USD","AGOX","BK4614","IXN","IE0009355771.USD","LU0353189763.USD","LU0943347566.SGD","IE00BJTD4N35.SGD","HK0000819398.USD","SG9999014575.USD","LU1804176565.USD","LU2764262908.HKD","LU1674673428.USD","LU2506951958.HKD","LU0094547139.USD","IE00B1BXHZ80.USD","LU0225283273.USD","LU0353189680.USD","LU2271345857.HKD","LU0266013472.USD","IE00B775H168.HKD","LU1861127337.USD","SMETAmain","FBY","LU0708995401.HKD","LU2237443549.SGD","EYES","FCOM","IE00B3M56506.USD","LU0114720955.EUR","LU0788109477.HKD","LU1992135472.HKD","LU0210528500.USD","LU0823434583.USD","LU1291159041.SGD","LU1564329032.USD","BK4524","LU0124676726.USD","LU2764263039.SGD","LU2272731865.HKD","LU0347712357.USD","IE0034235303.USD","LU2931357623.SGD","LU0994945656.USD","XLC","LU1069347547.HKD","LU1244550577.SGD","LU1670711123.USD","BK4525","IE00B4R5TH58.HKD","BK4503","LU0265550946.USD","LU0648000940.SGD","BK4504","BK4588","LU0251131958.USD","NVYY","LU0345770993.USD","LU0985489474.SGD","LU2417539215.USD","LU2471134952.CNY","LU0138981039.USD","LU2148611432.USD","LU1064131342.USD","LU1069344957.HKD","IE00BK4W5L77.USD","LU1127390331.HKD","LU2896262040.SGD","SG9999014542.SGD","LU0323239441.USD","IE00B19Z8W00.USD","LU1670710661.SGD","BK4613","LU1935042991.SGD","NVDS.UK","LU0068578508.USD","LU2294711713.HKD","LU2473716301.USD","OGIG","LU0342679015.USD","IE00BDCRKT87.USD","LU0256863902.USD","LU2244417387.USD","LU0719512351.SGD","LU0310800379.SGD","LU0912757837.SGD","LU2746668974.SGD","LU0345774631.USD","LU1791710582.SGD","PLOO","IE00B7SZLL34.SGD","ADBU","LU2242650005.HKD","IE00B19Z9P08.USD","LU2462591277.SGD","LU2023250330.USD","IE0004445239.USD","LU0878866978.SGD","IE00BZ1G4Q59.USD","LU0868494708.USD","IE00B19Z9Z06.USD","LU1267930227.SGD","LU2125154935.USD","BK4535","LU2077746001.SGD","LU2125909593.SGD","LU0012050646.USD","LU2720916845.USD","LU0689472784.USD","LU0552385451.USD","LU0310800965.SGD","BK4107","LU1564329461.SGD","SG9999001424.SGD","LU0082616367.USD","LU0238689110.USD","LU1261432733.SGD","LU2125909247.SGD","LU1979441026.SGD","LU1035773651.USD","LU2471134879.HKD","LU0130517989.USD","LU1691799644.USD","META","LU1121112475.USD","IE00BQXX3C00.GBP","LU0109392836.USD","ADBE","IE00B19Z3581.USD","FDTX","AIPI","LU0175139822.USD","LU1066051811.HKD","SOXY","LU0061475181.USD","PLTL","TTEQ","LU0323240290.USD","LU1935042215.USD","LU1551013425.SGD","LU0672654240.SGD","LU0208291251.USD","SGXZ57979304.SGD","LU1119994496.HKD","LU1974910355.USD","LU1989771016.USD","LU0203201768.USD","LU1564329115.USD","LU0314104364.USD","LU0823421333.USD","LU1301847155.USD","BK4082","LU1035775433.USD","SG9999015945.SGD","LU2458330169.SGD","NVDU","PLTU","LU0210536198.USD","LU1244550494.USD","LU0345770308.USD","LU0187121727.USD","SPTE","SNVDAmain","LU1989764748.USD","LU1983260115.SGD","LU2552382215.SGD","LU2860962120.EUR","LU2168563687.JPY","NVDD","IE00B2B36J28.USD","PLYY","SG9999014898.SGD","LU1712237335.SGD","BK4507","LU2237443465.HKD","IE00BMPRXN33.USD","LU0069063385.USD","IE00B4JS1V06.HKD","LU0689626769.HKD","LU1941712348.USD","LU1093756325.SGD","BK4529","LU2357305700.SGD","ANV","LU2404859741.USD","LU0820561818.USD","LU2237443622.USD","LU1674673691.USD","BHVN","LU2430703178.SGD","LU0979878070.USD","IE0002141913.USD","LU2357125470.USD","LU2471134523.USD","HK0000914660.USD","NVDX","LU0029864427.USD","LU1046421795.USD","LU0683600562.USD","LU0949170426.SGD","METW","LU0882574139.USD","LU1839511570.USD","LU2168564495.EUR","LU0690374961.EUR","LU2506951792.HKD","LU1815336760.USD","LU1066051225.USD","IE00B5949003.HKD","IE00BJJMRY28.SGD","LU1868836591.USD","LU2108987350.USD","LU1814569148.SGD","JGRO","IE0002270589.USD","LU0203347892.USD","IE00BWXC8680.SGD","LU1267930813.SGD","LU0316494557.USD","LU0648001328.SGD","LU0127658192.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662791203","title":"Spyre股價下跌，因關節炎藥物未達研發目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2662791203","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662791203?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:29","pubTimestamp":1787736543,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre股价下跌，因关节炎药物未达研发目标8月26日-** 药物研发公司Spyre Therapeutics（SYRE.O）的股价在盘前交易中下跌11.35%，报95.17美元** Spyre的试验性药物SPY072在中期临床试验中改善了类风湿性关节炎的症状(link)，但其疗效未达到将其开发为该病单药治疗方案的内部目标** 该研究针对中重度类风湿性关节炎患者（其病情对先前治疗反应不佳","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4T44N0LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103784641","title":"Spyre Therapeutics盤前股價重挫12.4% 實驗性藥物未達類風濕關節炎單藥治療開發門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=1103784641","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103784641?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:00","pubTimestamp":1787734809,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics股价在盘前交易时段大幅下跌12.4%，此前该公司宣布其一款实验性药物未能达到类风湿关节炎单药治疗开发所需的疗效阈值。这一消息令市场投资者颇感意外，引发对该生物科技公司研发管线前景的重新评估。受此利空冲击，该股在常规交易开始前即遭遇显著抛售压力，反映出市场对候选药物临床价值的疑虑正在加深。分析人士指出，未能跨越预设的疗效门槛意味着该药物作为单一疗法的开发路径将面临重大调整，公司或需重新考量其战略布局。投资者正密切关注公司后续的研发决策及可能的替代方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158063890","title":"Spyre Therapeutics公司——療效幅度未達公司預設目標，類風濕關節炎候選藥物SPY072單藥療法開發優先級或將調整","url":"https://stock-news.laohu8.com/highlight/detail?id=1158063890","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158063890?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688131,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics公司近日披露，其类风湿关节炎在研药物SPY072在临床试验中展现的疗效幅度未能达到公司预先设定的目标阈值。这一结果意味着，该公司此前规划的单药疗法开发路径——即将SPY072作为独立治疗方案推进的优先策略——如今面临重新审视与调整的现实压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107207144","title":"Spyre Therapeutics公司：Spy072聯合Il17-a/F治療化膿性汗腺炎（HS）預計於2027年末或2028年初啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1107207144","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107207144?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688130,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc宣布，其候选药物Spy072与Il17-a/F联合疗法用于治疗化脓性汗腺炎（HS）的计划，预计将在2027年末或2028年初推进。这一时间表标志着该公司在炎症性疾病领域管线布局的重要节点，也反映出其对该联合方案临床开发节奏的审慎把控。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157101849","title":"Spyre Therapeutics——Spy072在多項終點指標上較安慰劑展現統計學顯著優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=1157101849","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157101849?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688129,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics宣布，其候选药物Spy072在多项临床试验终点上，相较于安慰剂组，取得了具有统计学意义的显著改善。这一积极结果标志着该药物在治疗潜力上迈出了坚实一步，为后续研发注入了强劲动力。尽管具体数据细节尚未完全披露，但公司方面对Spy072的前景表达了高度信心，并计划加速推进其临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103864507","title":"Spyre Therapeutics公布Spy072 Skyway二期試驗類風濕關節炎亞研究頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103864507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103864507?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:02","pubTimestamp":1787688128,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics今日宣布，其Spy072在Skyway二期试验中针对类风湿关节炎亚研究的顶线结果已正式揭晓。这一里程碑式的数据发布，为该公司在自身免疫性疾病领域的研发管线注入了新的看点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661227372","title":"美國法院在DNA測序專利糾紛案中裁定Guardant公司支付2.45億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661227372","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661227372?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 19:21","pubTimestamp":1787570491,"startTime":"0","endTime":"0","summary":"美国法院在DNA测序专利纠纷案中裁定Guardant公司支付2.45亿美元路透8月24日-TwinStrand Biosciences周一表示，美国一家法院裁定Guardant Health公司侵犯了涉及DNA测序技术的专利，并责令其向TwinStrand Biosciences和华盛顿大学支付超过2.452亿美元的赔偿金。法院裁定，Guardant必须就其11项被认定侵犯专利的产品及服务在美国的销售额，支付6%的专利使用费，直至2033年3月相关专利到期为止。TwinStrand表示，该判决所涵盖的产品和服务约占Guardant在侵权期间总收入的90%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4T44L0SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4585","EKG","GDOC","GNOM","BK4551","PTH","BK4196","BK4535","LFSC","FFOX","HELX","GNMX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}]}}